TABLE 3.

Estimated Risk for ASD and DD Associated With Maternal Reported SSRI Use During Pregnancy

	Boys and Girls		Boys Only
	Unadjusted	Adjusteda	Unadjusted	Adjusteda
Total sample (N = 966)
ASD versus TD
Pregnancy	1.52 (0.65–3.53)	1.55 (0.59–4.08)	2.68 (1.07–6.73)*	2.92 (1.07–7.93)*
Trimester 1	1.32 (0.53–3.34)	1.38 (0.48–4.01)	2.76 (1.04–7.32)*	3.22 (1.17–8.84)*
Trimester 2	0.85 (0.30–2.42)	0.89 (0.24–3.24)	1.73 (0.53–5.67)	2.25 (0.54–9.42)
Trimester 3	1.15 (0.41–3.19)	1.18 (0.35–4.02)	2.40 (0.75–7.65)	2.91 (0.76–11.10)
DD versus TD
Pregnancy	2.03 (0.68–6.07)	1.62 (0.59–4.42)	4.60 (1.37–15.43)*	3.39 (0.98–11.75)
Trimester 1	1.21 (0.32–4.61)	1.05 (0.31–3.54)	3.69 (0.94–14.46)	3.26 (0.84–12.71)
Trimester 2	2.34 (0.67–8.19)	1.96 (0.64–6.06)	5.87 (1.40–24.67)*	4.41 (1.01–19.17)*
Trimester 3	2.68 (0.80–9.00)	2.19 (0.74–6.49)	6.82 (1.71–27.12)**	4.98 (1.20–20.62)*
Anxiety/mood disorder history subset (N = 229)
ASD versus TD
Pregnancy	1.51 (0.59–3.86)	1.86 (0.76–4.58)	2.85 (0.99–8.19)	3.17 (0.91–11.00)
Trimester 1	1.39 (0.50–3.84)	1.70 (0.66–4.37)	3.25 (1.07–9.85)*	3.52 (0.93–13.34)
Trimester 2	0.83 (0.28–2.47)	1.12 (0.40–3.11)	1.67 (0.48–5.79)	1.80 (0.39–8.37)
Trimester 3	1.05 (0.36–3.09)	1.43 (0.52–3.95)	2.17 (0.64–7.41)	2.45 (0.54–11.22)
DD versus TD
Pregnancy	1.79 (0.54–5.93)	1.44 (0.44–4.75)	3.86 (0.99–14.99)	2.30 (0.55–9.62)
Trimester 1	1.07 (0.26–4.51)	0.99 (0.26–3.83)	3.27 (0.73–14.76)	2.21 (0.52–9.39)
Trimester 2	1.92 (0.51–7.25)	1.76 (0.47–6.60)	4.28 (0.93–19.61)	2.62 (0.54–12.80)
Trimester 3	2.17 (0.60–7.86)	1.88 (0.51–6.88)	4.91 (1.13–21.37)*	2.83 (0.60–13.43)

Data are presented as ORs (95% CIs) and were weighted to adjust for selection bias. *P ≤ .05, **P ≤ .01.

^aAdjusted for regional center, child’s year of birth, and birthplace of mother.